Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its decision to spin out its own candidate into a separate company. In September, Tiziana ...

Induction therapy with a novel interleukin 6 (IL-6) inhibitor for active ulcerative colitis yielded significantly higher rates of clinical response, remission, and mucosal healing than placebo, ...

Interleukin-6 (IL-6) is a pleiotropic cytokine secreted by T cells and macrophages to activate immune responses during infection or after trauma. IL-6 plays an important role in a number of bodily ...

Besides being an immune protein, IL-6 is also a pyrogen and is responsible for fever in autoimmune, infectious, or non-infectious diseases. IL-6 is produced in the body, wherever there is inflammation ...

However, imbalances of IL-6 — too much or too little — can cause disease, even in the absence of infection. Excess IL-6 is central to the pathogenesis of inflammatory reactions like rheumatoid disease ...

A phase 2 trial of I-Mab’s olamkicept in ulcerative colitis patients has met its primary endpoint. The study provides early evidence that the IL-6 inhibitor improves outcomes including rectal bleeding ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. WASHINGTON — Patients with inflammatory arthritis who ...

Your doctor has recommended expanding your treatment plan for rheumatoid arthritis (RA) to include an interleukin 6 (IL-6) inhibitor — a biologic that’s often prescribed when conventional ...

Vaccine immunotherapy targeting interleukin 6 (IL-6) has shown promising results in the treatment of inflammatory osteoarthritis of the knee, according to a phase 1 double-blind controlled study.

Interleukin 6 receptor (IL-6r) inhibition is a promising approach for the treatment of calcium pyrophosphate deposition disease (CPPD), although no prospective studies have been conducted to date.